A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes

Summary

This is a study of select drug therapies in patients with salivary gland cancer. The study has two phases: a molecular profiling phase (phase 1) and a treatment phase (phase 2).

Based on the Molecular profiling results in phase the participants will receive matched treatment if a specific aberration is identified or will receive treatment with Selinexor if unmatched and no druggable aberration is identified.

Conditions

• Salivary Gland Cancer
• Metastatic
• Advanced
• Recurrent

Interventions

DRUG

Selinexor

If no "druggable" aberrations are identified on the molecular profiling analysis, then patients will receive unmatched treatment with Selinexor, a selective inhibitor of nuclear export (SINE).

DRUG

EGFR or HER2 Inhibitor

If specific "druggable" aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with EGFR or HER2 Inhibitor

DRUG

FGFR Inhibitor

If specific "druggable" aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with FGFR Inhibitor

DRUG

C-KIT Inhibitor

If specific "druggable" aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with C-KIT Inhibitor

DRUG

Anti-androgen

If specific "druggable" aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with Anti-androgens

DRUG

NOTCH Inhibitor

If specific "druggable" aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with NOTCH Inhibitor

DRUG

MEK or PI3K Inhibitor

If specific "druggable" aberrations are identified on the molecular profiling analysis, then patients will receive matched treatment with MEK or PI3K Inhibitor

Sponsors & Collaborators

• University Health Network, Toronto

  lead OTHER

Principal Investigators

• Anna Spreafico · Princess Margaret Cancer Centre

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2014-06-30

Primary Completion

2023-06-30

Completion

2023-06-30

Countries

• Canada

Study Locations